latest-news-headlines Market Intelligence /marketintelligence/en/news-insights/latest-news-headlines/five-prime-bristol-myers-drug-combo-fails-to-benefit-pancreatic-cancer-patients-57156695 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Five Prime, Bristol-Myers drug combo fails to benefit pancreatic cancer patients

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Five Prime, Bristol-Myers drug combo fails to benefit pancreatic cancer patients

Five Prime Therapeutics Inc. said a combination of its therapy cabiralizumab with Bristol-Myers Squibb Co.'s Opdivo failed to improve survival rate in patients with pancreatic cancer.

The randomized clinical trial evaluated the combination therapy in 160 patients with advanced pancreatic cancer that progressed during or after one line of chemotherapy. "Pancreatic cancer is a difficult disease to treat, and unfortunately the combination of cabiralizumab and Opdivo with and without chemotherapy did not show any meaningful benefit over standard of care chemotherapy in this randomized, controlled phase 2 trial," said Helen Collins, executive vice president and chief medical officer of Five Prime.

The primary goal of the study was to increase the survival in patients without the disease getting worse to up to 12 months.

Bristol-Myers does not have near term plans to sponsor additional development of cabiralizumab, Five Prime said. However, Bristol-Myers will continue to evaluate the drug in ongoing studies and may assess development opportunities in the future.